Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Generic drug

Vinorelbine Tartrate

Medicare prescription drug cost, prescriptions and prescribers, 2024

$18K

Medicare cost, 2024

Medicare drug plans spent $17,650 on Vinorelbine Tartrate in 2024, for 128 prescriptions and refills filled by 22 patients. Spending rose 32% from 2023 to 2024.

Medicare cost, 2024

$18K

+32.4% from 2023

Prescriptions

128

$137.89 per claim

Patients

22

17 prescribers

Total spending, 2024

$18K

$802.26 per patient

Questions and answers

How much does Medicare spend on Vinorelbine Tartrate?

Medicare prescription drug plans paid $18K for Vinorelbine Tartrate in 2024, for 128 prescriptions and refills to 22 patients (up 32.4% from 2023). The average cost per claim was $137.89.

Which state spends the most on Vinorelbine Tartrate?

New York had the highest Medicare cost for Vinorelbine Tartrate in 2024: $4,711 for 32 claims, followed by New Jersey ($2,470).

Who prescribes Vinorelbine Tartrate the most?

Trina Poretta, hematology-oncology in Voorhees, NJ, had the highest Medicare cost for Vinorelbine Tartrate in 2024: 36 claims costing $2,470.

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

Medicare spending on Vinorelbine Tartrate was $18K in 2024, after a high of $28K in 2020.

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Top prescribers of Vinorelbine Tartrate, 2024

By Medicare drug cost

PrescriberTypeClaimsPatientsCost
Trina Poretta Voorhees, NJHematology-Oncology36Under 11$2,470
Songchuan Guo Brooklyn, NYHematology-Oncology16Under 11$947

Prescriber data by year

YearPrescribersClaimsPatientsCost
20222710428$23K
2023198920$13K
20241712822$18K

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
Sagent Pharmace99$13K
Actavis/TevaTEVA logoTEVA29$4,994

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube